About LogicBio TherapeuticsA preclinical-stage company with a mission to develop cures for life-threatening diseases, LogicBio combines the best of gene therapy and genome-editing technology. Founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Children’s Medical Research Institute in Sydney – the company’s core platform includes its proprietary GeneRide technology and synthetic gene-therapy vectors derived from naturally occurring human adeno-associated viruses. LogicBio designed its approach to harness the natural power of homologous recombination - enabling precise, site-specific transfer of the genetic material without the use of promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases - focusing first on inborn errors of metabolism, where there are few, if any, treatment options. A number of the company’s discoveries have been featured in leading science publications and conferences. A private company, LogicBio is based in Cambridge, Massachusetts, with a research group in Tel Aviv.
Founders: Adi Barzel Ph.D., Mark Kay M.D. Ph.D. and Leszek Lisowski Ph.D.
President & CEO: Frederic Chereau
12 articles with LogicBio Therapeutics
Following last year’s stellar initial public offering in October, where it raised $80.5 million, about $10 million over initial expectations, LogicBio Therapeutics is planning a gene-editing clinical trial in children.
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
10/31/2018October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
Chardan announced today that the firm acted as lead manager in the initial public offering of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), raising aggregate gross proceeds of approximately $70.0 million. LogicBio began trading on the NASDAQ Capital Market on October 19, 2018.
Genome editing company adds drug development expert in pursuit of breakthrough medicines for pediatric patients
Preclinical data demonstrate potential for LB-001 to address the underlying cause of MMA
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
LogicBio Therapeutics, Inc. announced the appointment of Sandra Poole as chief operating officer, and Paul Herzich as senior director of manufacturing.
LogicBio Therapeutics today announced the expansion of its leadership team with the appointment of four seasoned industry leaders